BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23561712)

  • 21. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH.
    Osman NI; Chapple CR; Tammela TL; Eisenhardt A; Oelke M
    World J Urol; 2015 May; 33(5):697-706. PubMed ID: 25712312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective study of conservatively managed acute urinary retention: prostate size matters.
    Kumar V; Marr C; Bhuvangiri A; Irwin P
    BJU Int; 2000 Nov; 86(7):816-9. PubMed ID: 11069406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Reten-World survey of the management of acute urinary retention: preliminary results.
    Emberton M; Fitzpatrick JM
    BJU Int; 2008 Mar; 101 Suppl 3():27-32. PubMed ID: 18307683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction.
    Alan McNeill S
    Eur Urol; 2004 Mar; 45(3):325-32. PubMed ID: 15036678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.
    Maldonado-Ávila M; Manzanilla-García HA; Sierra-Ramírez JA; Carrillo-Ruiz JD; González-Valle JC; Rosas-Nava E; Guzman-Esquivel J; Labra-Salgado IR
    Int Urol Nephrol; 2014 Apr; 46(4):687-90. PubMed ID: 24061764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
    Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
    J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does sildenafil enhance the effect of tamsulosin in relieving acute urinary retention?
    Sharifi SH; Mokarrar MH; Khaledi F; Yamini-Sharif R; Lashay A; Soltani MH
    Int Braz J Urol; 2014; 40(3):373-8. PubMed ID: 25010303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.
    Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G
    J Urol; 2013 Jan; 189(1 Suppl):S122-8. PubMed ID: 23234617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
    Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized Crossover Comparison of the Short-Term Efficacy and Safety of Single Half-Dose Silodosin and Tamsulosin Hydrochoride in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Takeshita H; Moriyama S; Arai Y; Washino S; Saito K; Chiba K; Horiuchi S; Noro A
    Low Urin Tract Symptoms; 2016 Jan; 8(1):38-43. PubMed ID: 26789541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study.
    Takahashi H; Kubono S; Taneyama T; Kuramoto K; Mizutani H; Tanaka N; Yoshida M
    Drugs R D; 2019 Mar; 19(1):47-55. PubMed ID: 30607819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.
    Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G
    J Urol; 2009 Jun; 181(6):2634-40. PubMed ID: 19371887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
    McNeill SA; Hargreave TB;
    J Urol; 2004 Jun; 171(6 Pt 1):2316-20. PubMed ID: 15126812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is the double dose alpha-blocker treatment superior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia?
    Kara O; Yazici M
    Urol J; 2014 Jul; 11(3):1673-7. PubMed ID: 25015615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
    Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
    Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia.
    Lucas MG; Stephenson TP; Nargund V
    BJU Int; 2005 Feb; 95(3):354-7. PubMed ID: 15679793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does acute urinary retention respond to alpha-blockers alone?
    McNeill SA
    Eur Urol; 2001 Mar; 39 Suppl 6():7-12. PubMed ID: 11306895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH.
    Wu YJ; Dong Q; Liu LR; Wei Q
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):79-84. PubMed ID: 22986578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of in-and-out catheterization as a way of trial without catheterization strategy for treatment of acute urinary retention induced by benign prostate hyperplasia: variables predicting success outcome.
    Ko YH; Kim JW; Kang SG; Jang HA; Kang SH; Park HS; Moon du G; Cheon J; Kim JJ; Lee JG
    Neurourol Urodyn; 2012 Apr; 31(4):460-4. PubMed ID: 22331691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistive index as risk factor for acute urinary retention in patients with benign prostatic hyperplasia.
    Shinbo H; Kurita Y; Takada S; Imanishi T; Otsuka A; Furuse H; Nakanishi T; Mugiya S; Ozono S
    Urology; 2010 Dec; 76(6):1440-5. PubMed ID: 20646746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.